Be Bio’s New $130m Raise Will Advance B-Cell Therapies Toward The Clinic
Biotech is developing engineered B-cell therapeutics for rare diseases and cancer. They should offer greater duration and better tolerability than T-cell therapies, the company claims.
You may also be interested in...
Breyanzi’s list price is $410,300. The CD19-targeting CAR-T therapy previously known as liso-cel has a lot of ground to make up following competitors Yescarta and Kymriah.
Private Company Edition: TVM, Focus/MD Anderson and RA Capital launched new venture capital funds. Also, LianBio’s $310m crossover financing, AavantiBio’s Sarepta-backed $107m series A and Sirnaomics’ $105m series D led recent VC rounds.
The FDA placed a hold on the Phase II study of SRP-5051, which uses the company’s next-generation peptide conjugation technology, but Sarepta thinks it can address safety questions in short order.